Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Amatuximab

EU orphan designation number: EU/3/13/1222   
Active ingredient: Amatuximab
Indication: Treatment of malignant mesothelioma
Sponsor: Eisai Europe Limited
European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
21/01/2014 Centralised Orphan - Designation EMA/OD/108/13 (2014)292 of 16/01/2014